Related Experiment Video

Updated: Apr 25, 2026

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.4K

Associations between CD36 gene polymorphisms and susceptibility to coronary artery heart disease

Y Zhang1, Z Y Ling1, S B Deng1

  • 1Department of Cardiology, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.

Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Medicas E Biologicas
|August 15, 2014
PubMed

Insights

The CD36 gene

Area of Science:

  • Genetics and Cardiovascular Disease Research
  • Molecular Biology and Disease Association Studies

Background:

  • The relationship between CD36 gene polymorphisms and coronary artery heart disease (CHD) susceptibility remains unclear.
  • Understanding genetic factors like CD36 polymorphisms is crucial for identifying individuals at higher risk for CHD.

Purpose of the Study:

  • To investigate the association between CD36 gene polymorphisms (rs1761667 and rs3173798) and the risk of developing coronary artery heart disease (CHD).
  • To analyze CD36 mRNA expression and plasma oxidized low-density lipoprotein (ox-LDL) levels in relation to specific CD36 genotypes in CHD patients and controls.

Main Methods:

  • Genotyping of CD36 polymorphisms (rs1761667, rs3173798) using polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP).
  • Quantification of CD36 mRNA expression via real-time quantitative PCR and plasma ox-LDL levels using ELISA.
  • Statistical analysis including logistic regression to determine the association between genotypes and CHD risk.

Main Results:

  • The genotype distribution of rs1761667 differed significantly between CHD patients and controls, with a higher frequency of the AG genotype in CHD patients.
  • Plasma ox-LDL levels were significantly higher in individuals with the AG genotype compared to GG and AA genotypes.
  • CD36 mRNA expression was elevated in CHD patients, particularly in those with the AG genotype of rs1761667, and the AG genotype was associated with an increased risk of CHD.

Conclusions:

  • The rs1761667 polymorphism in the CD36 gene is closely associated with the development of CHD in the Chongqing Han population.
  • The AG genotype of rs1761667 may serve as a genetic susceptibility factor for coronary artery heart disease.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

11.7K
Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing ChIP-seq

Published on: April 19, 2013

23.8K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
156
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
80
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
12.3K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189